Silence Therapeutics plc

NASDAQ:SLN

Biotechnology

Healthcare
$19.82 +2.81%

+$0.19 today

Market cap
$936.18M
Beta
1.48
P/E (TTM)
-3.9
EPS (TTM)
-$1.80
52W Low $4.19High $8.40

Volume 1.47M

Average 0.31M

SLN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Silence Therapeutics plcNASDAQ: SLN

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 72.3%

Gross margin was 72.3% in Q1 FY2026, up 10.3 pp from a year earlier. On a trailing-twelve-month basis it was 66.4%. Over 3 fiscal years it widened by 23.7 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
72.3%+7.6 pp QoQ
Last fiscal yearDec 2025
61.5%-11.2 pp YoY
LTMMar 2026
66.4%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+10.3 pp——
1 year-11.2 pp——
3 years+23.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
61.5%
Year-over-year change
—

Gross Margin vs competitors

How SLN compares with its peers on the latest reported figures

  • SLN's LTM Mar 2026 gross margin of 66.4% is the 7th highest of the 8 companies compared; the peer median is 93.8%.
  • Over three fiscal years its change of +23.7 pp compares with a peer median of -10.7 pp.
SLN Competitors Peer median
Gross Margin for SLN and competitors
Company Period LTM level YoY 3-year change
RNAAtrium Therapeutics, Inc.FY2025100.0% ——
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 202699.6% -0.4 pp+4.8 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 202698.2% -0.6 pp+0.7 pp
WVEWave Life Sciences Ltd.LTM Mar 202693.8% -4.1 pp-20.7 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202691.2% -8.8 pp-4.5 pp
PRQRProQR Therapeutics N.V.LTM Mar 202689.7% -10.3 pp-17.0 pp
SLNSilence Therapeutics plcLTM Mar 202666.4% —+23.7 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 202662.4% -19.4 pp-25.1 pp
ADRXADARx Pharmaceuticals, Inc.—— ——
BNTCBenitec Biopharma Inc.FY2025— ——
Peer median (excluding SLN) 93.8%-6.5 pp-10.7 pp

Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · GBP
FY2025
Dec 2025 · USD
Revenue12.42M17.65M25.38M43.26M559K
Cost of Revenue7.46M10.97M10.32M11.81M215K
Gross Profit4.96M6.68M15.06M31.45M344K
Gross Margin39.9%37.8%59.3%72.7%61.5%
Research & Development30.77M35.5M44.03M67.88M67.75M
Selling, General & Admin20.01M20.94M20.64M26.88M22.34M
Operating Expenses50.77M56.44M64.66M94.77M90.1M
Depreciation & Amortization427K485.86K498K593K555K
EBITDA(45.42M)(39.94M)(49.78M)(48.99M)(88.05M)
EBITDA Margin-365.9%-226.2%-196.2%-113.2%-15750.6%
Operating Income(45.81M)(49.76M)(49.6M)(63.32M)(89.75M)
Operating Margin-369.0%-281.9%-195.5%-146.4%-16056.0%
Interest Income10K226K1.45M4.47M3.48M
Interest Expense8K47K34K00
Other Income / Expenses(42K)9.29M(706K)18.86M1.15M
Income Before Tax(45.86M)(40.47M)(50.31M)(44.46M)(88.6M)
Pre-Tax Margin-369.4%-229.3%-198.3%-102.8%-15849.9%
Income Tax Expense(6.45M)560.85K(7.04M)845K11K
Net Income(39.41M)(41.03M)(43.27M)(45.31M)(88.61M)
Net Margin-317.4%-232.4%-170.5%-104.7%-15851.9%
EPS (Basic)(1.35)(3.78)(3.48)(2.37)(1.89)
EPS (Diluted)(1.35)(3.78)(3.48)(2.37)(1.89)
Weighted Avg Shares29.65M10.73M12.36M15.42M47.23M
Weighted Avg Shares (Diluted)29.65M10.73M12.36M15.42M47.23M

Silence Therapeutics plc

NASDAQ:SLN

Intrinsic Alpha fair value

Locked

Current Price

$19.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.